ALIMERA SCIENCES INC Uncategorized Contracts & Agreements

55 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Alimera Sciences, Inc. 2024 Equity Inducement Plan
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2024
Omnibus Exit Fee Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders,...
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2023
Chairman Emeritus Agreement, dated as of August 1, 2023 by and between Alimera Sciences, Inc. and C. Daniel Myers
ALIMERA SCIENCES INC
Pharmaceuticals
GA
2023
Description of Securities
ALIMERA SCIENCES INC
Pharmaceuticals
2022
Description of Securities
ALIMERA SCIENCES INC
Pharmaceuticals
2021
Description of Securities
ALIMERA SCIENCES INC
Pharmaceuticals
2020
Exit Fee Agreement dated as of December 31, 2019, by and among Alimera Sciences, Inc., Solar Capital Ltd. as collateral agent, and the Lenders
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2020
Form of Alimera Sciences, Inc. Deduction Agreement
ALIMERA SCIENCES INC
Pharmaceuticals
GA
2019
Exit Fee Agreement dated as of January 5, 2018 by and among Alimera Sciences, Inc., Solar Capital Ltd. as collateral agent, and the Lenders
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2018
CONFIDENTIAL TREATMENT REQUESTED
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2016
EXHIBIT 10.41 CONFIDENTIAL TREATMENT REQUESTED
ALIMERA SCIENCES INC
Pharmaceuticals
2013
Interim Condensed Consolidated Financial Statements (unaudited)
ALIMERA SCIENCES INC
Pharmaceuticals
2012
EX-101 INSTANCE DOCUMENT
ALIMERA SCIENCES INC
Pharmaceuticals
2011
delay in or failure to obtain regulatory approval of the Companys product candidates
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2011
delay in or failure to obtain regulatory approval of the Companys product candidates
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2011
Entry into a Definitive Material Agreement
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2010
Entry into a Definitive Material Agreement
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2010
Entry into a Definitive Material Agreement
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2010
Entry into a Definitive Material Agreement
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2010
CONFIDENTIAL TREATMENT REQUESTED COMMERCIAL CONTRACT MANUFACTURING AGREEMENT Dated as of February 5, 2010 By and Between Alimera Sciences, Inc. And Alliance Medical Products, Inc.
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2010
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
2010
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
2010
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
GA
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
GA
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
NY
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In December 2009 we received the month 24 clinical readout from our FAME Study. Based upon our analysis of this data, we plan to file an NDA in...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In the fourth quarter of 2009 we will receive a month 24 readout from the FAME Study. Based on an analysis of this readout we plan to pursue an...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In the fourth quarter of 2009 we will receive a month 24 readout from the FAME Study. Based on an analysis of this readout we plan to pursue an...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009
Pursue FDA Approval for Iluvien. In the fourth quarter of 2009 we will receive a month 24 readout from the FAME Study. Based on an analysis of this readout we plan to pursue an...
ALIMERA SCIENCES INC
Pharmaceuticals
DE
2009